Monoclonal antibody with use investigating MVCD1, angiogenesis and various cancers.
| Inventor | Institute |
|---|---|
| Roy Bicknell | University of Oxford |
| Cat. #: | 151223 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell signaling and signal transduction;Metabolism;Tissue-specific biology |
| Application: | ELISA ; IHC ; WB |
| Target: | Vascular Endothelial Growth Factor (VEGF) |
| Reactivity: | Human ; Mouse ; Primate |
| Clone: | VG76e |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | Monoclonal antibody with use investigating MVCD1, angiogenesis and various cancers. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG1 kappa |
| Molecular weight: | 38-44 kDa |
| Immunogen: | Human VEGF189 expressed in E. coli. |
| Immunogen Uniprot ID: | P15692 |
| Myeloma used: | P3/NS1/1-Ag4.1 |
| Target background: | VEGF is a 34-43 kD polypeptide growth factor, part of the PDGF family. There are 7 homo-dimeric isoforms (A-G) with VEGF 121, VEGF 165 and VEGF189 being the most extensively studied (F,D and B respectively). They are generated by alternative splicing and binding to VEGF receptors (FLT-1 and KDR) which are selectively expressed on vascular endothelial cells. VEGF elicits mitogenic effects on endothelial cells and is strongly angiogenic, with a role in cancer and metastasis. VEGF is involved in vasculogenesis and endothelial growth. VEGF expression is potentiated, and the protein is secreted by tumour cells in response to hypoxia, by activated oncogenes, growth factors, nitric oxide and a variety of cytokines. Defects in VEGFA are linked to MVCD1 (microvascular complications of diabetes type 1) and VEGF polymorphisms are associated with susceptibility to multiple cancers, e.g. glioma, HCC, ovarian, bladder, prostate, breast cancer etc. VEGF is an angiogenic growth factor and a prognostic indicator for cancer when detected in serum. This antibody binds VEGF-A. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | Store at -20° C frozen. Avoid repeated freeze / thaw cycles |
| Shipping conditions: | Dry ice |
| References: |
Kimoto et al. 2019. Nucleic Acids Res. 47(16):8362-8374. PMID: 31392985. Tan et al. 2017. Sci Rep. 7(1):3504. PMID: 28615707. LeonhĤuser et al. 2017. J Transl Med. 15(1):3. PMID: 28049497. Butler et al. 2011. Am J Physiol Cell Physiol. 301(3):C653-66. PMID: 21653901. Contributions of VEGF to age-dependent transmural gradients in contractile protein expression in ovine carotid arteries. de Queiroz et al. 2010. J Vet Diagn Invest. 22(1):105-8. PMID: 20093695. Vascular endothelial growth factor expression and microvascular density in soft tissue sarcomas in dogs. Mariani et al. 2006. Theriogenology. 66(6-7):1715-20. PMID: 16569426. Immunohistochemical localization of VEGF and its receptors in the corpus luteum of the bitch during diestrus and anestrus. Brown et al. 2005. Br J Cancer. 92(9):1696-701. PMID: 15841086. Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma. Bouziotis et al. 2003. Anticancer Res. 23(3A):2167-71. PMID: 12894592. Samarium-153 and technetium-99m-labeled monoclonal antibodies in angiogenesis for tumor visualization and inhibition. Zhang et al. 1998. J Pathol. 185(4):402-8. PMID: 9828839. Validation of anti-vascular endothelial growth factor (anti-VEGF) antibodies for immunohistochemical localization of VEGF in tissue sections: expression of VEGF in the human endometrium. Epstein et al. 1975. J Am Podiatry Assoc. 65(12):1131-6. PMID: 1238455. Malpractice and PSROs. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151016 | Anti-CyclinA [E72.1] |
Key Info
Anti-CyclinA [E72.1]
|
View Tool | |||||||||||||||||||
| 151022 | Anti-IL12 [1-1A4] |
Key Info
Anti-IL12 [1-1A4]
|
View Tool | |||||||||||||||||||
| 151023 | Anti-IL12 [1-1D5] |
Key Info
Anti-IL12 [1-1D5]
|
View Tool | |||||||||||||||||||
| 151033 | Anti-HSVUL42 [13C9] |
Key Info
Anti-HSVUL42 [13C9]
|
View Tool | |||||||||||||||||||
| 151036 | Anti-ICAM1 [15.2] |
Key Info
Anti-ICAM1 [15.2]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.